Clinical Trial Update: SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating SHR-1701 in combination with Fluzoparib for non-small cell lung cancer (lung squamous cell carcinoma).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Squamous Cell Carcinoma
• Non-small Cell Lung Carcinoma

Drugs mentioned

• Fluzoparib (fluzoparib)
• SHR-1701

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN